Citation·page:ea-biosecurity-scope:fn3

Is EA Biosecurity Work Limited to Restricting LLM Biological Use? - Footnote 3

Verdictpartial85%

1 check · 4/3/2026

The claim that IBBIS was launched by NTI in 2024 is not directly supported by the source. The source states that the Common Mechanism was developed in partnership with the International Technical Consortium for DNA Synthesis Screening, which was launched by the Nuclear Threat Initiative (NTI) in partnership with the World Economic Forum in 2019. The claim that IBBIS is led by Piers Millett is not directly supported by the source. Piers Millett is listed as an author in one of the publications. The claim that IBBIS is headquartered in Geneva is supported by the source, but the claim that IBBIS was launched in 2024 is not.

Our claim

entire record

No record data available.

Source evidence

1 src · 1 check

ibbis.bio/our-work/common-mechanism/resource

partial85%Haiku 4.5 · 4/3/2026

NoteThe claim that IBBIS was launched by NTI in 2024 is not directly supported by the source. The source states that the Common Mechanism was developed in partnership with the International Technical Consortium for DNA Synthesis Screening, which was launched by the Nuclear Threat Initiative (NTI) in partnership with the World Economic Forum in 2019. The claim that IBBIS is led by Piers Millett is not directly supported by the source. Piers Millett is listed as an author in one of the publications. The claim that IBBIS is headquartered in Geneva is supported by the source, but the claim that IBBIS was launched in 2024 is not.

Case № page:ea-biosecurity-scope:fn3Filed 4/3/2026Confidence 85%